Download PDF
Am J Perinatol 2023; 40(04): 394-399
DOI: 10.1055/s-0041-1728826
Original Article

Prenatal Low-Dose Aspirin Use Associated with Reduced Incidence of Postpartum Hypertension among Women with Preeclampsia

Eleanor Christenson
1   Internal Medicine Resident, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri
,
Molly J. Stout
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan
,
Dominique Williams
3   Division of Medicine, Cardiovascular, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri
,
Amanda K. Verma
3   Division of Medicine, Cardiovascular, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri
,
Victor G. Davila-Roman
3   Division of Medicine, Cardiovascular, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri
,
Kathryn J. Lindley
4   Division of Medicine, Obstetrics and Gynecology, Cardiovascular, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri
› Author Affiliations Funding This study was supported by The Foundation for Barnes Jewish Hospital Womens Heart Health Fund and the American College of Cardiology, Missouri Chapter Research Award.
› Further Information
   Permissions and Reprints

Abstract

Objective Postpartum hypertension (PP-HTN), defined as systolic/diastolic blood pressure (SBP/DBP) ≥140/90, on two occasions at least 4 hours apart after delivery occurs in up to 50% of preeclamptic pregnancies, and is associated with adverse maternal outcomes. Excessive production of antiangiogenic factors (i.e., soluble fms-like tyrosine kinase 1 [sFLT1]) and reduced levels of proangiogenic factors (i.e., placental growth factor [PlGF]) are associated with preeclamptic pregnancies. The aim of this study was to identify clinical risk factors and/or serum biomarkers associated with PP-HTN in preeclampsia.

Study Design Preeclamptic women (n = 82, aged ≥18 years) were prospectively enrolled in an observational study. Serial blood pressures were obtained through the labor course and until 48 hours postpartum, and serum was obtained within 24 hours postpartum. Statistical analysis was performed by using Student's two-tailed t-test and Fisher's exact test.

Results Baseline comorbidities and antihypertensive use were similar among those who developed PP-HTN and those who did not. Among preeclamptic patients, 33% developed PP-HTN; these had significantly more severe preeclampsia features versus no PP-HTN (96 vs. 78%, p = 0.05). PP-HTN was associated with higher re-hospitalization rates (26 vs. 6%, p = 0.01). Among those taking low-dose aspirin (ASA) for preeclampsia prophylaxis (n = 12), PP-HTN was significantly less frequent versus those not taking low-dose ASA (0 vs. 22%, p = 0.007). Low-dose ASA use was associated with significantly lower peripartum sFLT1 levels (4,650 ± 2,335 vs. 7,870 ± 6,282 pg/mL, p = 0.03) and sFLT1/PlGF ratio (397 ± 196 vs. 1,527 ± 2,668, p = 0.03).

Conclusion One-third of women with preeclampsia develop PP-HTN; these patients have more severe preeclampsia and have higher re-hospitalization rates. Prenatal low-dose ASA use was associated with significantly lower incidence of PP-HTN, reduced levels of antiangiogenic factors, and lower 6-week re-hospitalization rates. These findings, if replicated, may have clinical implications on the use of low-dose ASA during pregnancy to reduce incidence of postpartum HTN.

Key Points

  • Postpartum hypertension is common in preeclampsia.

  • Prenatal aspirin may reduce postpartum hypertension.

  • Prenatal aspirin may reduce sFLT1 levels.

Keywords

preeclampsia - postpartum hypertension - aspirin - pregnancy - women


Publication History

Received: 14 September 2020

Accepted: 02 March 2021

Article published online:
03 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Spaan J, Peeters L, Spaanderman M, Brown M. Cardiovascular risk management after a hypertensive disorder of pregnancy. Hypertension 2012; 60 (06) 1368-1373
    CrossrefPubMedGoogle Scholar
  • 2 Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123 (24) 2856-2869
    CrossrefPubMedGoogle Scholar
  • 3 Verbeek AL, Verbeek AJ. Timely assessment of cardiovascular risk after preeclampsia. Womens Health (Lond) 2014; 10 (06) 557-559
    CrossrefPubMedGoogle Scholar
  • 4 Ghossein-Doha C, van Neer J, Wissink B. et al. Pre-eclampsia: an important risk factor for asymptomatic heart failure. Ultrasound Obstet Gynecol 2017; 49 (01) 143-149
    CrossrefPubMedGoogle Scholar
  • 5 Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy?. Atherosclerosis 2004; 175 (02) 189-202
    CrossrefPubMedGoogle Scholar
  • 6 Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith G, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ 2007; 335 (7627): 978
    CrossrefPubMedGoogle Scholar
  • 7 van Rijn BB, Nijdam ME, Bruinse HW. et al. Cardiovascular disease risk factors in women with a history of early-onset preeclampsia. Obstet Gynecol 2013; 121 (05) 1040-1048
    CrossrefPubMedGoogle Scholar
  • 8 Breathett K, Muhlestein D, Foraker R, Gulati M. Differences in preeclampsia rates between African American and Caucasian women: trends from the National Hospital Discharge Survey. J Womens Health (Larchmt) 2014; 23 (11) 886-893
    CrossrefPubMedGoogle Scholar
  • 9 Rosenbloom JI, Lewkowitz AK, Lindley KJ. et al. Expectant management of hypertensive disorders of pregnancy and future cardiovascular morbidity. Obstet Gynecol 2020; 135 (01) 27-35
    CrossrefPubMedGoogle Scholar
  • 10 Theilen LH, Fraser A, Hollingshaus MS. et al. All-cause and cause-specific mortality after hypertensive disease of pregnancy. Obstet Gynecol 2016; 128 (02) 238-244
    CrossrefPubMedGoogle Scholar
  • 11 LeFevre ML, Force USPST. U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 161 (11) 819-826
    CrossrefPubMedGoogle Scholar
  • 12 ACOG Committee opinion no. 743: low-dose aspirin use during pregnancy. Obstet Gynecol 2018; 132 (01) e44-e52
    CrossrefPubMedGoogle Scholar
  • 13 Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol 2017; 8: 261
    CrossrefPubMedGoogle Scholar
  • 14 Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285 (12) 1607-1612
    CrossrefPubMedGoogle Scholar
  • 15 Tuzcu ZB, Asicioglu E, Sunbul M, Ozben B, Arikan H, Koc M. Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women. Am J Obstet Gynecol 2015; 213 (04) 533.e1-533.e7
    CrossrefPubMedGoogle Scholar
  • 16 Possomato-Vieira JS, Khalil RA. Mechanisms of endothelial dysfunction in hypertensive pregnancy and preeclampsia. Adv Pharmacol 2016; 77: 361-431
    CrossrefPubMedGoogle Scholar
  • 17 Jardim LL, Rios DR, Perucci LO, de Sousa LP, Gomes KB, Dusse LM. Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia?. Clin Chim Acta 2015; 447: 34-38
    CrossrefPubMedGoogle Scholar
  • 18 Bian Z, Shixia C, Duan T. First-trimester maternal serum levels of sFLT1, PGF, and ADMA predict dysfunction in the pathogenesis of preeclamspia. PLoS One 2015; 10: e0124684
    CrossrefPubMedGoogle Scholar
  • 19 Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 2005; 57 (5 Pt 2): 1R-7R
    CrossrefPubMedGoogle Scholar
  • 20 Di Marco GS, Reuter S, Hillebrand U. et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 2009; 20 (10) 2235-2245
    CrossrefPubMedGoogle Scholar
  • 21 Rana S, Powe CE, Salahuddin S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125 (07) 911-919
    CrossrefPubMedGoogle Scholar
  • 22 Heimberger S, Mueller A, Ratnaparkhi R, Perdigao JL, Rana S. Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension. Pregnancy Hypertens 2020; 20: 124-130
    CrossrefPubMedGoogle Scholar
  • 23 Lin L, Li G, Zhang W, Wang YL, Yang H. Low-dose aspirin reduces hypoxia-induced sFlt1 release via the JNK/AP-1 pathway in human trophoblast and endothelial cells. J Cell Physiol 2019; 234 (10) 18928-18941
    CrossrefPubMedGoogle Scholar
  • 24 Li C, Raikwar NS, Santillan MK, Santillan DA, Thomas CP. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta 2015; 36 (04) 446-453
    CrossrefPubMedGoogle Scholar
  • 25 Gestational Hypertension and Preeclampsia. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol 2020; 135 (06) e237-e260
    CrossrefPubMedGoogle Scholar
  • 26 Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103 (16) 2055-2059
    CrossrefPubMedGoogle Scholar
  • 27 Clapp MA, Little SE, Zheng J, Robinson JN. A multi-state analysis of postpartum readmissions in the United States. Am J Obstet Gynecol 2016; 215 (01) 113.e1-113.e10
    CrossrefPubMedGoogle Scholar
  • 28 Petersen EE, Davis NL, Goodman D. et al. Vital signs: pregnancy-related deaths, united states, 2011-2015, and strategies for prevention, 13 states, 2013-2017. MMWR Morb Mortal Wkly Rep 2019; 68 (18) 423-429
    CrossrefPubMedGoogle Scholar
  • 29 Maynard SE, Min JY, Merchan J. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111 (05) 649-658
    CrossrefPubMedGoogle Scholar
  • 30 Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122 (05) 478-487
    CrossrefPubMedGoogle Scholar
  • 31 Petrozella L, Mahendroo M, Timmons B, Roberts S, McIntire D, Alexander JM. Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period. Am J Obstet Gynecol 2012; 207 (02) 140.e20-140.e26
    CrossrefPubMedGoogle Scholar
  • 32 Wolf M, Hubel CA, Lam C. et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004; 89 (12) 6239-6243
    CrossrefPubMedGoogle Scholar
  • 33 Armaly Z, Jadaon JE, Jabbour A, Abassi ZA. Preeclampsia: novel mechanisms and potential therapeutic approaches. Front Physiol 2018; 9: 973
    CrossrefPubMedGoogle Scholar
  • 34 Bramham K, Nelson-Piercy C, Brown MJ, Chappell LC. Postpartum management of hypertension. BMJ 2013; 346: f894
    CrossrefPubMedGoogle Scholar
  • 35 Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36 (05) 416-441
    CrossrefPubMedGoogle Scholar
  • 36 Powles K, Gandhi S. Postpartum hypertension. CMAJ 2017; 189 (27) E913
    CrossrefPubMedGoogle Scholar
  • 37 Walters BNJ, Walters T. Hypertension in the puerperium. Lancet 1987; 2 (8554): 330
    CrossrefPubMedGoogle Scholar
  • 38 Mahajan A, Kemp A, Hawkins TL, Metcalfe A, Dowling S, Nerenberg K. Postpartum hypertensive disorders in the emergency department - a retrospective review of local practice in Calgary, Alberta. Pregnancy Hypertens 2020; 19: 212-217
    CrossrefPubMedGoogle Scholar
  • 39 Meeks JR, Bambhroliya AB, Alex KM. et al. Association of Primary Intracerebral Hemorrhage With Pregnancy and the Postpartum Period. JAMA Netw Open 2020; 3 (04) e202769
    CrossrefPubMedGoogle Scholar